Financial Data and Key Metrics Changes - For the full year 2025, the company facilitated 97,348 certified loans and recorded total revenue of $93.2 million, resulting in adjusted EBITDA of $15.6 million [9] - In Q4 2025, the company facilitated 19,308 loans, generating revenue of $19.3 million and adjusted EBITDA of $2.8 million [9][34] - Operating expenses decreased by 9.3% year-over-year to $13.9 million in Q4 2025 compared to $15.4 million in Q4 2024 [36] - Net income for Q4 2025 was $1.7 million, a significant improvement from a net loss of $144 million in Q4 2024 [36] Business Line Data and Key Metrics Changes - The ApexOne Auto platform was launched in Q4 2025, with two customers in the prime credit auto segment, contributing to a more than doubled pipeline since launch [18] - The profit tier unit economics for the 2025 vintage continue to be booked at a constrained 72.5% loss ratio, with expectations to perform closer to a mid-60% loss ratio [17] Market Data and Key Metrics Changes - The loan-to-share ratio for credit unions improved to 83.2% in Q4 2025, indicating a healthier lending environment [20] - The company observed a 20% year-over-year increase in application flow through February 2026 [12] Company Strategy and Development Direction - The company aims to maintain tighter underwriting standards and appropriate pricing to ensure disciplined, profitable growth across multiple credit cycles [6][11] - The introduction of the ApexOne Auto platform allows the company to serve the entire spectrum of credit scores, enhancing its market position [18] - The company plans to continue innovating and deepening relationships with credit unions, focusing on responsible growth and maintaining a disciplined approach to underwriting and pricing [20][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capture incremental certification and partner expansion within the credit union market, especially if interest rates decline further in 2026 [22] - The company anticipates certified loan guidance of 100,000-110,000 for 2026, reflecting an 8% increase over 2025 results [27] Other Important Information - The company paid down approximately $50 million of its senior secured term loan in Q4 2025, which is expected to save approximately $575,000 in quarterly interest expenses [28][39] - The company repurchased approximately 564,000 shares at an average price of $66 per share during the quarter [28] Q&A Session Summary Question: Concerns about AI disruption - Management acknowledged the use of AI in their tools and models, emphasizing that their proprietary data and machine learning capabilities are superior to standard AI tools [44][46] Question: Cert outlook for Q1 and 2026 - Management explained that the first quarter's lower certs are influenced by the elimination of super thins and tighter credit standards, but they expect growth to resume incrementally throughout 2026 [48][50] Question: Health of the credit union channel - Management reported that credit unions are looking to grow in a disciplined manner, with improved loan-to-share ratios and a focus on responsible growth [60][62] Question: Current outlook for delinquencies - Management indicated that delinquencies for the most recent vintage are running about 200 basis points better than previous years, reflecting improved credit quality [70][72]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from transitioning to direct management of Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [7][8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on delivering current initiatives, scaling areas with traction, and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [4][5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce expansion and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, aiming for higher growth rates than 2025 [13] - The company is focused on a mixture of revenue contributors, including e-commerce, municipal orders, and international expansion [15][17] - Management is confident in the potential for improvement in profitability and revenue growth [45] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [74] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - A mixture of e-commerce, municipal orders, and international expansion is expected to drive revenue [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: What municipalities besides New York City are evaluating Evolve? - Baltimore and Chicago are mentioned, with ongoing assessments in various neighborhoods [32] Question: Will the sales team be expanded? - Yes, the company plans to expand the sales team to maximize B2B sales efforts [61]

Financial Data and Key Metrics Changes - Revenue from continuing operations increased by 3.1% in Q4 2025 compared to Q4 2024, reaching $15.2 million, while consolidated adjusted EBITDA rose by 7.8% to $3.6 million [9][20] - For the full year 2025, revenue was $54.9 million, up from $52.2 million in 2024, and consolidated net income improved to $2.9 million from a loss of $5.8 million in 2024 [21][22] - Unrestricted cash and cash equivalents at the end of Q4 2025 stood at $23.6 million, down from $25.1 million in the prior year [22] Business Line Data and Key Metrics Changes - System-wide sales decreased by 3.9% to $130 million in Q4 2025, while comp sales were down 3.8% [18] - For the full year, system-wide sales were flat at $532 million, with comp sales declining by 0.4% [18] Market Data and Key Metrics Changes - The total clinic count at year-end 2025 was 960, down from 967 clinics in the prior year, with 885 franchise clinics and 75 company-owned clinics [19] - The company refranchised 41 clinics and closed 36 clinics during 2025 [19] Company Strategy and Development Direction - The company is on track to complete the first phase of its transformation journey, Joint 2.0, by the end of 2026, transitioning to a pure-play franchisor model [5][28] - Future growth strategies include expanding operations into new channels and markets, focusing on health trends and integrated treatments [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in improving operating leverage and financial position through refranchising and cost-saving initiatives [28] - The company anticipates that 2026 will be more profitable than 2025 due to refranchising efforts and realignment of corporate costs [24] Other Important Information - The company repurchased 1.1 million shares for $9 million in Q4 2025 and a total of 1.3 million shares for $11.3 million in 2025 [9][22] - The company expects system-wide sales in 2026 to range from $519 million to $552 million, with comp sales projected between -3% to 3% [22] Q&A Session Summary Question: Can you share the attrition and new patient add metrics? - Management noted that new patient flow has been the weakest component of active member growth, but early signs from new marketing efforts are positive [33][34] Question: How are you evolving marketing initiatives for 2026? - The focus remains on shifting investment from local to national marketing to amplify brand awareness, with ongoing adjustments to creative messaging and addressing shifts in search behaviors due to AI [36][37] Question: How did the three-tiered pricing pilot go? - The $10 pricing increase showed more benefit compared to the $2 increase, and further testing is ongoing before broader rollout [39][40] Question: How did comp sales progress throughout the quarter? - Comp sales were down the most in November but improved in December, with expectations for better performance in the second half of the year [46][47] Question: What specific leading indicators give confidence that comps will improve in 2026? - Management highlighted early signs of improvement in leads and new patient acquisition, with expectations for better performance in the second half of the year due to easier comparisons [52][55] Question: Can you elaborate on growth initiatives and capital allocation? - Investments will focus on technology improvements and user interface enhancements for Wellness Coordinators, with ongoing negotiations for RD territory buybacks [70][73]

Financial Data and Key Metrics Changes - In Q4 2025, the company delivered $18.3 million in bookings, near the high end of the guided range, with strong contributions from IP products and TCAD solutions [14] - Revenue reached $18.3 million in Q4, above the high end of the guidance, with TCAD and IP revenue growing 34% and almost 3x respectively [14] - GAAP gross margin in Q4 was 83.3%, and non-GAAP gross margin was 85.6%, reflecting a sequential increase of roughly five full points [15][16] - GAAP operating loss improved to $6.8 million, while non-GAAP operating loss was just over $1 million, ahead of expectations [18][19] - Cash and marketable securities at quarter end was $18.3 million, with expectations to approach operating cash flow breakeven in Q2 and positive operating cash flow in Q3 [19][20] Business Line Data and Key Metrics Changes - TCAD business saw a 70% sequential increase in bookings to $9.2 million and a 34% sequential increase in revenue to $8.7 million, driven by the adoption of the AI-driven FTCO solution [6][14] - The semiconductor IP business delivered record revenue and bookings of over $5 million in Q4, significantly driven by the Mixel acquisition [7][14] - EDA bookings and revenue declined significantly in Q4, with bookings just under $4 million and revenue of $4.4 million, following record performance in Q3 [10][15] Market Data and Key Metrics Changes - The APAC region contributed significantly to growth in Q4, accounting for 57% of total revenue, driven by the FTCO solution [15] - The MIPI PHY market is valued at over $300 million per year, with the company holding a relatively modest share, indicating potential for growth [8] Company Strategy and Development Direction - The company is focused on executing a turnaround plan, with an emphasis on AI-driven solutions and enhancing the TCAD business [4][5] - There is a commitment to reducing annualized non-GAAP operating expenses by at least $20 million, aiming for profitability at flat revenue [18] - The company is prioritizing core products in EDA and leveraging AI tools to improve software development and operational efficiency [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to recover faster than expected, with strong guidance for Q1 2026 [4][20] - The transition to AI-enabled sales is expected to be a long-term tailwind for the business, with significant opportunities identified in the semiconductor manufacturing process [5][13] - Management acknowledged the need for continued focus on execution and the importance of customer support while enhancing product development [11][12] Other Important Information - The company has seen a meaningful inflection in the semiconductor IP business, with expectations for steady growth in this area as they ramp MIPI PRO products [9] - The restructuring efforts have led to improved gross margins and increased R&D capacity, positioning the company for future growth [11][16] Q&A Session Summary Question: Growth priorities and execution - Management highlighted the need for financial flexibility and the successful execution of cost reduction programs, leading to improved morale and focus on new opportunities [22][25] Question: Revenue recognition for FTCO deal - A significant portion of the FTCO revenue was recognized in Q4, with the remainder to be recognized over the contract term [28][29] Question: Adoption process for FTCO - The efficiency in closing and ramping FTCO customers is expected to improve, with a growing pipeline of potential customers [35][36] Question: Segment bookings expectations for Q1 - Continued strength in TCAD is anticipated, with IP expected to remain stable and EDA to be flat sequentially [36] Question: Growth expectations from Mixel acquisition - The Mixel acquisition is expected to contribute to double-digit revenue growth, particularly in the second half of the year [46][51] Question: Performance expectations for business segments in 2026 - The fastest growth is expected in the IP segment, followed by TCAD, while EDA is anticipated to remain stable [55]

Jefferson Capital (NasdaqGS:JCAP) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Speaker7Good afternoon, and welcome to Jefferson Capital's fourth quarter and full year 2025 conference call. With us today are David Burton, Founder and Chief Executive Officer, and Christo Realov, Chief Financial Officer. As a reminder, this conference call is being recorded. This call may contain forward-looking statements regarding the company's plans, initiatives, and strategies, and the anticipated financial performance ...

Financial Data and Key Metrics Changes - For Q4 2025, diluted earnings per share increased by 23% year-over-year, while for the full year, it grew by 25% year-over-year [6][15] - Total operating revenue and other income rose by 107% year-over-year to $734 million in Q4, driven by the acquisition of Mercury and increased managed receivables [12] - Managed receivables increased by 37% year-over-year, with new account originations up 73% for the year [8] Business Line Data and Key Metrics Changes - The acquisition of Mercury Financial effectively doubled the size of the company's balance sheet to approximately $7 billion, adding over 1.3 million customers [4] - Purchase volume increased by 54% for Q4 year-over-year and by 32% for the full year [8] - The company acquired a $165 million retail credit portfolio from a competitor, enhancing its position in the point-of-sale market [6] Market Data and Key Metrics Changes - The competitive landscape remains robust, with record solicitations leading to some softening in response rates and marketing efficiency [9] - The company has seen stable consumer behavior, with consistent payment performance and stable delinquency trends [8] Company Strategy and Development Direction - The acquisition of Mercury is expected to enhance long-term earnings power through disciplined portfolio management and cost savings [4] - The company aims for long-term earnings growth of 20% or more annually while maintaining a return on average equity of 20% or greater [11] - The integration of Mercury is expected to be completed by early 2027, with ongoing realization of synergies and efficiencies [21] Management's Comments on Operating Environment and Future Outlook - Management anticipates a robust tax season, which may lead to a temporary slowdown in growth but will ultimately reduce delinquencies [29] - The company is well-positioned to respond to macroeconomic changes, including fluctuations in oil prices, by adjusting underwriting and pricing strategies [43] - Management expressed confidence in the long-term positioning of the company despite a competitive landscape [9] Other Important Information - The company ended the year with over $600 million in unrestricted cash and maintained a diversified funding model [7][15] - The integration of Mercury is progressing well, with operational efficiencies already being realized [5] Q&A Session Summary Question: Integration progress of Mercury - Management confirmed that the integration is ahead of schedule, with significant changes in portfolio terms already implemented [19][20] Question: Funding structure and macro concerns - Management stated that funding partners remain supportive, and the company has not seen any deterioration in funding availability [24][25] Question: Tax refund season implications - Management expects a robust tax season, which will lead to paydowns that may slow growth temporarily but benefit delinquencies in the long term [29][30] Question: Customer concentration risk - Management indicated that relationships with larger partners have evolved positively, and concentration risk is managed through a diversified portfolio [33][34] Question: Fair value mark insights - Management explained that the fair value mark was conservative due to the nature of newly acquired receivables and expected improvements over time [46][47]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $69.3 million, exceeding the high end of guidance, driven by higher variable revenue [21] - Adjusted EBITDA for Q4 2025 was $10.8 million, also above the high end of guidance, attributed to improved cost structure and operational execution [21] - Recurring revenue was $52.9 million, representing 89% of total revenue, while professional services revenue was $8.3 million, down 36% year-over-year [21] - Average revenue per customer increased by 9% year-over-year to $680,000 [22] - Cash on the balance sheet at the end of Q4 was $95 million [22] Business Line Data and Key Metrics Changes - Revenue from hosted services was $51 million, down 15% year-over-year [21] - The company signed 40 deals in Q4, including 4 new logos and 36 expansions, indicating a slight sequential increase in total deal value [18] - Over 20% of all conversations in Q4 leveraged Generative AI tools, showing strong adoption of AI capabilities [8] Market Data and Key Metrics Changes - The company is seeing strong traction in regulated industries such as banking, telecommunications, and airlines, with significant renewals from major players in these sectors [18] - The partnership with Google Cloud is yielding early results, including a multi-million dollar renewal through the Google Cloud Marketplace [10] Company Strategy and Development Direction - The company is focused on three primary areas: customer growth and retention, innovation in the Conversational Cloud platform, and expanding technology partnerships [4] - The launch of Syntrix is a key strategic growth opportunity, aimed at addressing market gaps in AI deployment assurance [6][7] - The company plans to complete its multi-year platform modernization in the first half of 2026, which is foundational for long-term scalability [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive net new ARR in the second half of 2026, despite expected revenue declines throughout the year [16][23] - The company anticipates that the launch of Syntrix will drive future growth and improve customer retention [25] - Management emphasized the importance of disciplined execution and cost management to support long-term value creation [25] Other Important Information - The company expects full-year 2026 revenue to range from $195 million to $207 million, with approximately 92% expected to be recurring [23] - Adjusted EBITDA for 2026 is expected to range from a loss of $4 million to a gain of $7 million [24] Q&A Session Summary Question: Can you walk us through the decrease in total OpEx for Q4? - Management indicated that the decrease was primarily due to a large restructuring executed in the prior quarter, with some one-time items but mainly structural changes [28] Question: How does positive net new ARR relate to expected revenue declines? - Management clarified that while they expect positive net ARR in the second half, historical customer losses will continue to impact revenue negatively throughout 2026 [30] Question: Can you expand on the demand for Syntrix and its development? - Management noted that initial demand was for simulation capabilities, but it evolved into a broader solution addressing compliance and governance challenges in AI deployment [36] Question: What is the pricing model for Syntrix? - The pricing model for Syntrix is conversation-based, allowing for consumption-based pricing that aligns with customer needs [42] Question: How does Google Cloud Marketplace impact the sales strategy? - Management stated that the Google Cloud Marketplace serves as a retention lever, simplifying procurement and potentially driving new business opportunities [46]

Financial Data and Key Metrics Changes - The company ended 2025 with $245.8 million in cash and investments and no debt on its balance sheet [9][23] - Revenue for Q4 2025 was $21.8 million, and for the full year, it was $55.2 million [24] - R&D expenses for Q4 2025 were $29.7 million, totaling $117.3 million for the year [24] - G&A expenses for Q4 2025 were $11.2 million, with a full-year total of $68.7 million [24] - The net loss for Q4 2025 was $36.1 million, or $1.78 per share, while the full-year net loss was $164.1 million, or $9.73 per share [24][25] Business Line Data and Key Metrics Changes - The company focused on advancing its immunology and inflammation pipeline, particularly the Treg biologic, rezpegaldesleukin [3][4] - Positive results were achieved in phase 2b studies for atopic dermatitis and alopecia areata, validating the efficacy of the Treg mechanism [4][5] - The atopic dermatitis market is projected to grow to approximately $35 billion by the mid-2030s, with only 10%-15% of patients currently receiving biologic treatments [5][6] Market Data and Key Metrics Changes - In the U.S., over 15 million people suffer from moderate to severe atopic dermatitis, presenting a significant market opportunity [5] - The competitive landscape for late-stage novel mechanisms of action (MOAs) has narrowed, positioning REZPEG favorably [6][7] Company Strategy and Development Direction - The company plans to initiate phase 3 studies for rezpegaldesleukin in June 2026, with a BLA submission targeted for 2029 [9][10] - The strategy includes leveraging a differentiated efficacy and safety profile for REZPEG, aiming to provide a better dosing regimen compared to existing treatments [6][7] - The company is also exploring additional indications for REZPEG, including type 1 diabetes and other autoimmune diseases [20][21] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of the Treg mechanism in addressing various diseases and expressed optimism about the potential for REZPEG to achieve significant market penetration [20][21] - The company anticipates that the phase 3 program will provide robust data supporting the efficacy and safety of REZPEG, which could lead to a strong competitive position in the market [9][10] Other Important Information - The company raised approximately $476 million in additional net cash through a public offering and ATM exercises since year-end 2025 [9][23] - The phase 3 program for atopic dermatitis will include both biologic-naive and treatment-experienced patients, with a focus on achieving significant clinical endpoints [10][11] Q&A Session Summary Question: What type of new data can be expected from the AAD conference? - The upcoming presentation will showcase additional effects of treatment with REZPEG and the potential for more patients to achieve SALT 20 responses [29][30] Question: Will ACQ-5 data be included in the phase 3 program? - Yes, ACQ-5 will be included, and efforts will be made to incorporate it into the label [36][37] Question: What is the formulation or device for REZPEG being considered? - The plan is to launch REZPEG in an auto-injector device, with weight-banded dosing for ease of administration [41][47] Question: How does REZPEG differentiate from other treatments in type 1 diabetes? - REZPEG offers an outpatient dosing regimen without the need for routine monitoring, contrasting with the more complex administration of other treatments [78][79]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $58.9 million, a 16% decrease year-over-year and a sequential decrease of 7% compared to Q3 2025, primarily due to challenges in the industrial end market and the divestiture of a mall-related business [14][15] - Gross profit for Q4 was $9.1 million, a decline of 15% year-over-year and a sequential decline of 21%, resulting in a gross margin of 15.5% [16] - SG&A expenses were $7.7 million, a 24% reduction year-over-year and a 17% reduction sequentially, attributed to headcount reductions and increased efficiencies [19] Business Line Data and Key Metrics Changes - The industrial end market faced significant volume declines, contributing to a $10.7 million reduction in quarterly revenue compared to the prior year [14][15] - Despite challenges in the industrial sector, the remaining two-thirds of the business saw modest growth of $7.4 million, or about 5% [15] - New business wins and wallet share initiatives launched in Q4 are expected to contribute positively in 2026 [15][18] Market Data and Key Metrics Changes - The overall pipeline remains healthy, but economic uncertainty has led to decision delays among potential clients [6] - The company has not lost any customers in the industrial end market, indicating strong relationships that may benefit from future recovery [5] Company Strategy and Development Direction - The company is focused on operational excellence initiatives to drive efficiencies and improve financial performance as market conditions normalize [8][13] - There is an emphasis on expanding wallet share with existing customers and onboarding new clients to enhance revenue streams [10][13] - The company aims to reduce debt and improve cash generation while continuing to invest in growth opportunities [23][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 was a challenging year due to volume declines from the industrial end market, but expressed confidence in the company's ability to recover as macroeconomic conditions improve [12][26] - The company is well-positioned to accelerate financial performance and drive shareholder value as conditions improve [26] Other Important Information - The company generated over $1 million in cash from operations and $1.7 million of free cash flow in Q4 [21] - The company reduced its debt by approximately $2 million in Q4, bringing the full-year debt reduction to $13.2 million, a 16.4% reduction [23] Q&A Session Summary Question: Update on KPIs and operational efficiency initiatives - Management stated that all KPIs and operational efficiency initiatives are on track, with positive trending despite the difficult volume environment [30][31] Question: Health of the vendor network - Management reported improved relationships with vendors, with vendors now accepting payment to term and experiencing the lowest service disruptions in history [32][33] Question: Cross-sell opportunities with industrial customers - Management indicated that if industrial clients expand operations, the company stands to benefit due to strong relationships and service satisfaction [34][36]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash equivalents and investments of $258.3 million, with an additional $23.7 million received from a favorable arbitration outcome [13][14] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, while the full year net loss was $189.9 million, or $0.87 per share [16][17] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [15][17] Business Line Data and Key Metrics Changes - The focus for 2026 is on delivering clinical milestones for cema-cel in ALPHA3 and ALLO-329 in RESOLUTION, with significant emphasis on the allogeneic CAR T platform [4][6] - ALPHA3 aims to redefine management of large B-cell lymphoma by testing early intervention with cema-cel [5][8] - ALLO-329 is designed for autoimmune diseases, targeting CD19 and CD70, with proof of concept data expected in June 2026 [6][10] Market Data and Key Metrics Changes - The company has over 60 active clinical sites across the U.S. and Canada, with plans to expand to Australia and South Korea [9] - The integration of cema-cel into community cancer centers is seen as a core advantage, expanding access to advanced cell therapy [9] Company Strategy and Development Direction - The company aims to validate its allogeneic platform as a scalable and accessible solution for cell therapy [4][6] - There is a strategic focus on prioritizing resources for programs with the greatest potential for demonstrating the advantages of allogeneic CAR T [6][12] - The company is positioned for long-term value creation with a cash runway extended into the first quarter of 2028 [15][17] Management's Comments on Operating Environment and Future Outlook - Management believes that the cell therapy landscape is shifting towards evidence-based practices, emphasizing data and disciplined execution [4] - The upcoming year is viewed as critical for generating proof points that could validate the allogeneic platform [4][6] - Management expressed confidence in the ability to execute through important inflection points with a focus on high-impact programs [17][18] Other Important Information - The company has made prudent use of its ATM equity facility, raising an additional $20.7 million year to date [14] - Guidance for operating cash expenses in 2026 is expected to be approximately $150 million, with GAAP operating expenses around $210 million [17] Q&A Session Summary Question: Safety parameters for ALPHA3 data update - Management plans to provide high-level safety information, focusing on serious adverse events and outpatient delivery feasibility [20][21] Question: Insights from ZUMA-7 MRD analysis - Management views the ZUMA-7 study as consistent with their expectations for MRD clearance and its correlation to clinical outcomes [23][24] Question: Interim analysis and MRD conversion - Management indicated that while MRD clearance may correlate with clinical outcomes, the relationship is not fully established [28][29] Question: Expectations for ALLO-329 data - The target product profile for ALLO-329 includes low or no lymphodepletion, with ongoing studies testing these parameters [31][32] Question: Market opportunity and stem cell positioning - Management is monitoring the evolving landscape of large B-cell lymphoma treatments and believes MRD positivity rates will remain largely unchanged [34][36] Question: Enrollment pace for ALPHA3 study - Enrollment is on track to be completed by the end of 2027, with MRD positivity rates consistent with expectations [67][68]